< Back to previous page
Researcher
Lieve Naesens
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 15
- Inhibition of lung inflammation in pneumonia induced by micro-organismsFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Development of modified anhydrohexitol nucleic acid (HNA) and altritol nucleic acid (ANA) antisense oligonucleotides to combat SARS-CoV-2From21 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Dual targeting of nsp12 and nsp15: a powerful concept to suppress coronavirus replication and transcriptionFrom1 Oct 2022 → TodayFunding: IOF - technology concept exploration
- Designing airway-targeted prodrug strategies for anti-respiratory virus therapeuticsFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Hitting coronavirus replication in its core by combined inhibition of the nsp12 polymerase and associated proteins of the replication-transcription complexFrom13 Sep 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Covalent locking of the influenza virus hemagglutinin prefusion structure: an innovative concept to create broadly protective influenza vaccinesFrom7 Sep 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Entry inhibitors for human respiratory virus SARS-CoV-2.From21 Aug 2017 → 6 Jun 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Automated real-time quantitative live cell analysisFrom1 Oct 2016 → 30 Sep 2018Funding: Fund Recuperation Fiscal Exemption
- Characterization of the influenza virus polymerase using T-705 and ribavirin and design of RNA chain terminating prodrugs of these unique antiviral agentsFrom1 Jan 2015 → 31 Dec 2017Funding: FWO research grant KAN
- An automated platform for multiparameter data collection on live pathogens of higher or unknown biosafety risk.From26 Jun 2014 → 31 Dec 2018Funding: Hercules - Large scale research infrastructure
Publications
1 - 10 of 179
- Novel 2-indolinone derivatives as promising agents against respiratory syncytial and yellow fever viruses(2024)
Authors: Lieve Naesens
- Exploration of 1,2,3-triazolo fused triterpenoids as inhibitors of human coronavirus 229E targeting the viral nsp15 protein(2024)
Authors: Annelies Stevaert, Benjamin Van Loy, Lieve Naesens, Wim Dehaen
- Amphiphilic Sialic Acid Derivatives as Potential Dual-Specific Inhibitors of Influenza Hemagglutinin and Neuraminidase(2023)
Authors: Lieve Naesens
- PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding(2023)
Authors: Evelien Vanderlinden, Arnaud Boonen, Sam Noppen, Maya Imbrechts, Robert Snoeck, Annelies Stevaert, Lieve Naesens, Graciela Andrei, Dominique Schols
- Entry inhibitors for human respiratory virus SARS-CoV-2.(2023)
Authors: Emiel Vanhulle, Kurt Vermeire, Piet Maes, Lieve Naesens, Dominique Schols
- Novel Polymyxin-Inspired Peptidomimetics Targeting the SARS-CoV-2 Spike:hACE2 Interface(2023)
Authors: Emiel Vanhulle, Sam Noppen, Lieve Naesens, Annelies Stevaert, Kurt Vermeire
- Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy(2022)
Authors: Annelies Stevaert, Elisabetta Groaz, Lieve Naesens
- Development and optimization of biologically contained Marburg virus for high-throughput antiviral screening(2022)
Authors: Bert Vanmechelen, Lieve Naesens, Kurt Vermeire, Piet Maes
- Synthesis of new N-(3-oxo-1-thia-4-azaspiro[4.5]decan-4-yl)pyridine-3-carboxamide derivatives and evaluation of their anti-influenza virus and antitubercular activities(2022)
Authors: Lieve Naesens
- Synthesis and Anticancer and Antiviral Activities of C-2′-Branched Arabinonucleosides(2022)
Authors: Lieve Naesens